A post hoc analysis of pooled data from three double-blind, placebo-controlled trials shows that the treatment abrocitinib is a safe and effective option for patients with moderate-to-severe atopic dermatitis across different racial and ethnic groups. Results from clinical trials with 945 patients, including 628 white patients, 204 Asian patients, 83 Black patients, and 37 Hispanic/Latino patients, showed that abrocitinib was more effective than a placebo in all racial, skin type, and ethnic subgroups. The effectiveness of abrocitinib was observed from week 2 and continued through week 12, and was generally well tolerated, although there were differences in the rates of discontinuation due to treatment-emergent adverse events among different racial and ethnic groups.
Source link
Safe and Effective for Atopic Dermatitis Across Races, Ethnicities
